Sorry, you need to enable JavaScript to visit this website.
  1. Home
  3. Science
  4. Clinical Trials
  5. Plain Language Study Results Summaries
  6. Bhv3000 202 Phase 2 Double Blind

A Study of Rimegepant in Adults With Refractory Trigeminal Neuralgia

BHV3000-202: Phase 2: A Double-Blind, Placebo Controlled, Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia

Category & Conditions: Neurological Diseases and Conditions
Medicine: Nurtec® ODT (Rimegepant)
ClinicalTrials.gov Identifier (NCT): NCT03941834
Protocol ID: BHV3000-202 (C4951014)
DownloadPrint

Open Plain Language Summary Result:

Click here